This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

China breaks new ground with reversal of first pharmaceutical deal

By MLex Staff ( July 25, 2025, 08:22 GMT | Comment) -- China’s antitrust regulator has broken new ground by unwinding a completed pharmaceutical acquisition, marking its first-ever full rollback of a consummated deal. In a historic move, the State Administration for Market Regulation ordered Wuhan Yongtong Pharmaceutical to divest its stake in Shandong Beida Gaoke Huatai Pharmaceutical. The case marks an evolution in how Chinese authorities deploy merger reviews — not just as a forward-looking tool to prevent anticompetitive outcomes, but increasingly as a means of correcting market distortions that have already materialized.China’s antitrust regulator has broken new ground by unwinding a completed pharmaceutical acquisition, marking its first-ever full rollback of a consummated deal....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login